When nanomedicines meet tropical diseases DOI Creative Commons
Eder Lilia Romero,

Katrien Van Bocxlaer,

Fábio Rocha Formiga

et al.

Beilstein Journal of Nanotechnology, Journal Year: 2024, Volume and Issue: 15, P. 830 - 832

Published: July 8, 2024

Keywords: Aedes aegypti; Chagas disease; leishmaniasis; nanomedicine; nanotechnology; neglected tropical diseases; schistosomiasis

Language: Английский

Mitochondrial Reactive Oxygen Species in Infection and Immunity DOI Creative Commons
Arunima Mukherjee, Krishna Ghosh, Sabyasachi Chakrabortty

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(6), P. 670 - 670

Published: June 8, 2024

Reactive oxygen species (ROS) contain at least one atom and or more unpaired electrons include singlet oxygen, superoxide anion radical, hydroxyl hydroperoxyl free nitrogen radicals. Intracellular ROS can be formed as a consequence of several factors, including ultra-violet (UV) radiation, electron leakage during aerobic respiration, inflammatory responses mediated by macrophages, other external stimuli stress. The enhanced production is termed oxidative stress this leads to cellular damage, such protein carbonylation, lipid peroxidation, deoxyribonucleic acid (DNA) base modifications. This damage may manifest in various pathological states, ageing, cancer, neurological diseases, metabolic disorders like diabetes. On the hand, optimum levels have been implicated regulation many important physiological processes. For example, generated mitochondria (mitochondrial mt-ROS), byproduct transport chain (ETC), participate plethora functions, which cell growth, proliferation, immune response regulation. In current review, we will focus on mechanisms mt-ROS regulate different pathways host context infection bacteria, protozoan parasites, viruses, fungi. We also discuss how these pathogens, turn, modulate evade immunity. conclude briefly giving an overview potential therapeutic approaches involving infectious diseases.

Language: Английский

Citations

16

Enhanced Nanogel Formulation Combining the Natural Photosensitizer Curcumin and Pectis brevipedunculata (Asteraceae) Essential Oil for Synergistic Daylight Photodynamic Therapy in Leishmaniasis Treatment DOI Creative Commons
Loretta Gasco,

Estela Mesquita Marques,

Daniele Stéfanie Sara Lopes Lera‐Nonose

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 286 - 286

Published: Feb. 21, 2025

Background/Objectives: Neglected tropical diseases (NTDs), such as leishmaniasis, remain a global health challenge due to limited therapeutic options and rising drug resistance. In this study, we developed an advanced nanogel formulation incorporating curcumin (CUR) Pectis brevipedunculata essential oil (EOPb) within F127/Carbopol 974P matrix enhance bioavailability efficacy against Leishmania (Leishmania) amazonensis (LLa) promastigotes. Methods: The chemical profile of EOPb was determined through GC-MS NMR analyses, confirming the presence key bioactive monoterpenes neral, geranial, α-pinene, limonene. (nGPC) optimized ensure thermosensitivity, stability, exhibiting sol–gel transition at physiological temperatures. Rheological analysis revealed that nGPC exhibited Newtonian behavior 5 °C, transitioning shear-thinning thixotropic characteristics 25 32 respectively. This facilitates its application controlled release, making it ideal for topical formulations. Dynamic light scattering (DLS) demonstrated maintained stable nanoscale structure with hydrodynamic radius below 300 nm, while Fourier-transform infrared spectroscopy (FTIR) confirmed strong molecular interactions between EOPb, CUR, polymer matrix. Biological assays significantly enhanced anti-promastigote activity compared free CUR OEPb. Results: At highest tested concentration (50 μg/mL 17.5 CUR) induced over 88% mortality in LLa promastigotes across 24, 48, 72 h, indicating sustained efficacy. Even lower concentrations, retained dose-dependent activity, suggesting synergistic effect EOPb. These findings highlight potential innovative nanocarrier daylight photodynamic therapy (dPDT) treatment leishmaniasis. Future studies will investigate underlying mechanisms synergism explore (PDT) further outcomes.

Language: Английский

Citations

0

Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis DOI Creative Commons
Damai Ria Setyawati, Fransiska Christydira Sekaringtyas, Riyona Desvy Pratiwi

et al.

Beilstein Journal of Nanotechnology, Journal Year: 2024, Volume and Issue: 15, P. 1105 - 1116

Published: Aug. 23, 2024

Over recent decades, nanomedicine has played an important role in the enhancement of therapeutic outcomes compared to those conventional therapy. At same time, nanoparticle drug delivery systems offer a significant reduction side effects treatments by lowering off-target biodistribution active pharmaceutical ingredients. Cancer represents most extensively studied nanotechnology application field pharmaceutics and pharmacology since first nanodrug for cancer treatment, liposomal doxorubicin (Doxil ® ), been approved FDA. The advancement its enormous technological success also included various other target diseases, including hepatic fibrosis. This confirms versatility improving activity. In this review, we summarize updates platforms efficacy regarding liver We emphasize challenges drugs penetrating biological barriers liver. After that, highlight design principles nanocarriers achieving improved antifibrosis through passive targeting strategies.

Language: Английский

Citations

1

Exploring the Influence of Acetylenic Acetogenin Unsaturation Patterns on Lipid Interface Interactions: Insights from Surface Chemistry, Rheology, and Spectroscopy DOI Creative Commons
Matheus Elias Rosa,

Ivanildo A. Brito,

João Henrique G. Lago

et al.

Results in Surfaces and Interfaces, Journal Year: 2024, Volume and Issue: unknown, P. 100306 - 100306

Published: Sept. 1, 2024

Language: Английский

Citations

1

Combination Therapy and Phytochemical-Loaded Nanosytems for the Treatment of Neglected Tropical Diseases DOI Creative Commons
Jacqueline Soto‐Sánchez,

Gilberto Garza-Treviño

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(10), P. 1239 - 1239

Published: Sept. 24, 2024

Background: Neglected tropical diseases (NTDs), including leishmaniasis, trypanosomiasis, and schistosomiasis, impose a significant public health burden, especially in developing countries. Despite control efforts, treatment remains challenging due to drug resistance lack of effective therapies. Objective: This study aimed synthesize the current research on combination therapy phytochemical-loaded nanosystems, which have emerged as promising strategies enhance efficacy safety. Methods/Results: In present review, we conducted systematic search literature identified several phytochemicals that been employed this way, with notable reducing parasite load liver spleen cases visceral well lesion size cutaneous leishmaniasis. Furthermore, they synergistic effect against Trypanosoma brucei rhodesiense rhodesain; reduce inflammation, parasitic myocardium, cardiac hypertrophy, IL-15 production Chagas disease; affect both mature immature stages Schistosoma mansoni, resulting improved outcomes compared administration alone or conventional drugs. Moreover, majority combinations studied demonstrated enhanced solubility, efficacy, selectivity, increased immune response reduced cytotoxicity. Conclusions: These formulations appear offer therapeutic benefits, although further is required validate their clinical humans potential improve affected populations.

Language: Английский

Citations

1

Epoxy-a-lapachone in nanosystem: a prototype drug for leishmaniasis assessed in the binomial BALB/c - Leishmania (Leishmania) amazonensis DOI Creative Commons

Juliana Figueiredo Peixoto,

Luiz Filipe Gonçalves-Oliveira, Geovane Dias-Lopes

et al.

Memórias do Instituto Oswaldo Cruz, Journal Year: 2024, Volume and Issue: 119

Published: Jan. 1, 2024

This perspective presents and supports arguments for a new formulation of epoxy-α-lapachone loaded microemulsion (ELAP-ME), nanosystem, as prototype drug the treatment leishmaniasis. The benefits ELAP multitarget compound, with properties that affect key physiological pathways Leishmania spp. are discussed. ELAP-ME demonstrated efficacy in murine infection models, particularly binomial BALB/c-Leishmania (Leishmania) amazonensis. Furthermore, it is proposed technological maturity be classified Technology Readiness Level 4 (TLR 4) within context innovative drugs American Cutaneous Leishmaniasis (ACL).

Language: Английский

Citations

1

When nanomedicines meet tropical diseases DOI Creative Commons
Eder Lilia Romero,

Katrien Van Bocxlaer,

Fábio Rocha Formiga

et al.

Beilstein Journal of Nanotechnology, Journal Year: 2024, Volume and Issue: 15, P. 830 - 832

Published: July 8, 2024

Keywords: Aedes aegypti; Chagas disease; leishmaniasis; nanomedicine; nanotechnology; neglected tropical diseases; schistosomiasis

Language: Английский

Citations

0